This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Questions about our CME?
Questions about our CME?
Advancing the Role of the SGLT2 Inhibitors in the T2D Treatment Paradigm

Advancing the Role of the SGLT2 Inhibitors in the T2D Treatment Paradigm

Format

Roundtable

Time to Complete

2 hours

Released

July 31, 2018

Expires

July 31, 2019
Add to Queue


Maximum Credits

2.00 / AMA PRA Category 1 CreditsTM

Accredited Provider

Jointly provided by Purdue University and Physicians' Education Resource®, LLC (PER®)

Commercial Supporter

Supported by an educational grant from Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC.

Program Description

Physicians’ Education Resource®, LLC, (PER®) is pleased to present the CME-certified online activity titled "Advancing the Role of the SGLT2 Inhibitors in the T2D Treatment Paradigm." This innovative activity is an archived version of the live-streamed Medical Crossfire® held on June 25, 2018 at the American Diabetes Association’s 78th Scientific Sessions.

Intended Audience

This activity is directed to endocrinologists.

Educational Objectives

After completing this activity, clinicians should be better able to:
  • Articulate reasons that persons with type 2 diabetes (T2D) fail to achieve target A1C goals and reduce cardiometabolic risk factors
  • List the potential clinical benefits for achieving glycemic control with newer therapies, especially SGLT2 inhibitors, in persons with T2D and cardiometabolic risk factors at various stages of the disease
  • Discuss results of recent large-scale cardiovascular outcomes trials in persons with T2D
  • Develop individualized approaches for effectively improving outcomes in persons with T2D and cardiometabolic risk factors

Conflict Of Interest Disclosure Policy

All faculty, staff and reviewers involved in the planning, review or presentation of continuing education activities provided by Purdue University College of Pharmacy are required to disclose to the audience any relevant commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships will be made in writing to the audience prior to the activity.

Faculty

Program Chair
Vivian Fonseca, MD

Professor of Medicine and Pharmacology
Assistant Dean for Clinical Research
Tullis Tulane Alumni Chair in Diabetes
Chief, Section of Endocrinology
Tulane University Health Sciences Center
New Orleans, LA

Dr. Fonseca discloses the following:
Grant/Research Support: Asahi, Bayer, Boehringer Ingelheim
Consultant/Speakers Bureau: AstraZzeneca, BI Lilly, Intarcia, Novo Nordisk, Sanofi-Aventis, Takeda; Other/Honoraria for CME Lectures: AstraZzeneca, BI Lilly, Intarcia, Novo Nordisk, Sanofi-Aventis, Takeda

Program Moderator
Stephen Brunton

Executive Director
Primary Care Metabolic Group (PCMG )
Palm Springs, CA

Dr. Brunton discloses the following:
Consultant/Speaker’s Bureau: Abbott Diabetes, AstraZeneca, Boehringer Ingelheim, Janssen, Lilly, Novo Nordisk, Sanofi

Program Faculty
Silvio E. Inzucchi, MD

Professor of Medicine
Clinical Chief, Endocrinology
Yale School of Medicine
Medical Director, Yale Diabetes Center
Yale-New Haven Hospital
New Haven, CT

Dr. Inzucchi discloses the following:
Consultant/Speaker’s Bureau: Janssen, VTV Pharmaceuticals
Other/Honoraria for CME Lectures: Clinical trial/steering/executive/publications committees: Astra Zeneca, Boehringer Ingelheim, Eisai (TIMI), Novo Nordisk, Sanofi/Lexicon
Data Monitoring Committee: Intarcia

James Januzzi, MD
Hutter Family Professor of Medicine
Harvard Medical School
Physician
Massachusetts General Hospital
Cardiometabolic Trials
Baim Institute for Clinical Research
Boston, MA

Dr. Januzzi discloses the following:
Grant/Research Support: Boehringer Ingelheim, Janssen
Consultant/Speakers Bureau: Janssen

Accredited Provider Disclosure

All additional planning committee members, staff and reviewers of Purdue University College of Pharmacy have no relevant financial relationships with commercial interests to disclose.

Publishing Staff Disclosures

All additional planning committee members, staff and reviewers of Physicians' Education Resource®, LLC have no relevant financial relationships with commercial interests to disclose.

Credit

2.00

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Purdue University College of Pharmacy and Physician’s Education Resource, LLC. Purdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

Purdue University College of Pharmacy designates this enduring activity for a maximum of 2.00 AMA PRA Category 1 Credit(s)TM .  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management.

Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Instructions

To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

For information about the accreditation of this program, please contact Dawn Sinclair, sinclaid@purdue.edu, Accreditation Coordinator for Purdue University College of Pharmacy’s Office of CE, regarding accreditation designation or Heather Holley, hholley@purdue.edu, Reconciliation and Outcomes Coordinator for Purdue University College of Pharmacy’s Office of CE, regarding CE credit received and/or certificates.

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue